Complete financial analysis of United Therapeutics Corporation (UTHR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- PhenixFIN Corporation 5.25% Notes due 2028 (PFXNZ) Income Statement Analysis – Financial Results
- Fuda Alloy Materials Co.,Ltd (603045.SS) Income Statement Analysis – Financial Results
- CITIC Telecom International Holdings Limited (1883.HK) Income Statement Analysis – Financial Results
- Beijing Worldia Diamond Tools Co.,Ltd. (688028.SS) Income Statement Analysis – Financial Results
- Liberta Co.,Ltd. (4935.T) Income Statement Analysis – Financial Results
United Therapeutics Corporation (UTHR)
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B | 1.63B | 1.73B | 1.60B | 1.47B | 1.29B | 1.12B | 916.08M | 743.18M | 603.83M | 369.85M | 281.50M | 210.94M | 159.63M | 115.92M | 73.59M | 53.34M | 30.12M | 5.73M | 2.05M | 400.00K | 100.00K |
| Cost of Revenue | 257.50M | 146.70M | 122.50M | 108.10M | 117.60M | 198.70M | 105.70M | 72.70M | 69.04M | 125.88M | 131.13M | 119.30M | 88.90M | 73.47M | 45.32M | 30.07M | 22.26M | 17.03M | 12.32M | 8.25M | 6.78M | 5.46M | 3.14M | 1.71M | 1.40M | 0.00 |
| Gross Profit | 2.07B | 1.79B | 1.56B | 1.38B | 1.33B | 1.43B | 1.62B | 1.53B | 1.40B | 1.16B | 985.86M | 796.78M | 654.28M | 530.37M | 324.53M | 251.43M | 188.68M | 142.60M | 103.60M | 65.34M | 46.56M | 24.66M | 2.59M | 343.47K | -1.00M | 100.00K |
| Gross Profit Ratio | 88.94% | 92.42% | 92.73% | 92.71% | 91.88% | 87.79% | 93.87% | 95.45% | 95.29% | 90.23% | 88.26% | 86.98% | 88.04% | 87.83% | 87.75% | 89.32% | 89.45% | 89.33% | 89.38% | 88.79% | 87.28% | 81.89% | 45.27% | 16.76% | -250.00% | 100.00% |
| Research & Development | 408.00M | 322.90M | 540.10M | 357.70M | 1.18B | 357.90M | 264.60M | 147.60M | 245.10M | 242.55M | 299.35M | 173.39M | 180.02M | 166.76M | 122.19M | 239.18M | 83.35M | 57.57M | 36.05M | 30.60M | 35.42M | 26.78M | 32.59M | 70.19M | 30.70M | 11.00M |
| General & Administrative | 395.30M | 416.20M | 402.60M | 369.00M | 275.50M | 206.70M | 265.80M | 232.20M | 358.32M | 299.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.44M | 16.94M | 11.74M | 5.00M | 0.00 |
| Selling & Marketing | 81.80M | 70.80M | 64.40M | 54.90M | 60.70M | 59.10M | 64.30M | 84.60M | 94.30M | 82.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.45M | 3.38B | 0.00 | 0.00 | 0.00 |
| SG&A | 477.10M | 487.00M | 467.00M | 423.90M | 336.20M | 265.80M | 330.10M | 316.80M | 452.61M | 381.29M | 394.01M | 201.75M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 54.03M | 24.66M | 21.53M | 22.67M | 15.89M | 16.94M | 11.74M | 5.00M | 2.40M |
| Other Expenses | 0.00 | -40.20M | 42.20M | 49.30M | 22.60M | -7.70M | 13.20M | 2.40M | 157.00K | 3.97M | 635.00K | 31.87M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 56.05M | 24.66M | 21.53M | 22.67M | 15.89M | 0.00 | -79.74K | -1.30M | 2.40M |
| Operating Expenses | 885.10M | 809.90M | 1.01B | 781.60M | 1.52B | 623.70M | 594.70M | 464.40M | 697.71M | 623.84M | 693.36M | 375.13M | 336.50M | 366.36M | 298.53M | 333.49M | 182.38M | 113.62M | 60.71M | 52.13M | 58.08M | 42.67M | 49.53M | 81.84M | 34.40M | 13.40M |
| Cost & Expenses | 1.14B | 956.60M | 1.13B | 889.70M | 1.64B | 822.40M | 700.40M | 537.10M | 766.75M | 749.72M | 824.49M | 494.43M | 425.40M | 439.83M | 343.85M | 363.55M | 204.64M | 130.65M | 73.02M | 60.38M | 64.87M | 48.12M | 52.67M | 83.55M | 35.80M | 13.40M |
| Interest Income | 162.70M | 45.20M | 16.70M | 28.60M | 44.20M | 28.60M | 10.90M | 3.50M | 0.00 | 0.00 | 3.83M | 3.94M | 3.45M | 2.94M | 5.15M | 11.03M | 13.60M | 10.70M | 5.36M | 2.99M | 2.44M | 4.95M | 10.02M | 10.69M | 0.00 | 0.00 |
| Interest Expense | 59.30M | 32.40M | 18.60M | 23.50M | 44.20M | 13.90M | 9.00M | 3.90M | 4.74M | 17.59M | 18.06M | 16.64M | 21.37M | 19.71M | 12.88M | 16.00K | 2.18M | 482.00K | 29.00K | 4.00K | 112.00K | 117.00K | 172.72K | 120.04K | 0.00 | 0.00 |
| Depreciation & Amortization | 53.20M | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M | 31.00M | 31.60M | 32.92M | 32.25M | 31.26M | 27.15M | 20.54M | 17.92M | 11.39M | 4.54M | 957.00K | 1.46M | 2.41M | 2.28M | 2.33M | 3.14M | 3.51M | -79.74K | -1.30M | -500.00K |
| EBITDA | 1.39B | 1.04B | 736.80M | 646.30M | -74.90M | 838.40M | 1.05B | 1.09B | 1.08B | 575.02M | 323.76M | 484.46M | 341.02M | 185.47M | 43.04M | -67.75M | 22.19M | 28.98M | 50.09M | 17.83M | -9.20M | -14.87M | -43.42M | -81.58M | -36.66M | -13.80M |
| EBITDA Ratio | 59.58% | 50.85% | 36.48% | 45.27% | -8.34% | 50.76% | 60.17% | 66.56% | 47.70% | 42.12% | 26.59% | 52.88% | 43.21% | 27.62% | 8.38% | -25.31% | 3.83% | 19.59% | 39.04% | 20.98% | -17.60% | -15.25% | -754.18% | -3,752.55% | -9,200.00% | -13,800.00% |
| Operating Income | 1.18B | 979.70M | 555.90M | 593.60M | -187.60M | 805.40M | 814.90M | 1.06B | 699.02M | 538.80M | 292.50M | 421.65M | 317.78M | 164.01M | 26.00M | -82.06M | 6.30M | 28.98M | 42.89M | 13.21M | -11.53M | -18.00M | -46.94M | -81.50M | -35.40M | -13.30M |
| Operating Income Ratio | 50.91% | 50.60% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 27.16% | 7.03% | -29.15% | 2.99% | 18.16% | 37.00% | 17.95% | -21.61% | -59.77% | -818.93% | -3,977.08% | -8,850.00% | -13,300.00% |
| Total Other Income/Expenses | 89.40M | -29.10M | 38.00M | 45.30M | 22.60M | -46.50M | -45.40M | -1.50M | 345.42M | -13.60M | -13.60M | 19.03M | -18.67M | -16.17M | -7.23M | 9.76M | 10.28M | 10.93M | 4.63M | 2.24M | 1.56M | -5.65M | 9.65M | -4.68M | 63.50K | 546.20K |
| Income Before Tax | 1.27B | 950.60M | 593.90M | 638.90M | -165.00M | 758.90M | 769.50M | 1.06B | 1.04B | 525.18M | 278.90M | 440.67M | 299.12M | 147.84M | 18.77M | -72.30M | 16.58M | 39.91M | 47.52M | 15.45M | -9.97M | -23.65M | -37.29M | -86.18M | -35.30M | -12.80M |
| Income Before Tax Ratio | 54.75% | 49.09% | 35.24% | 43.07% | -11.39% | 46.62% | 44.60% | 66.31% | 71.26% | 40.76% | 24.97% | 48.10% | 40.25% | 24.48% | 5.07% | -25.68% | 7.86% | 25.00% | 41.00% | 20.99% | -18.69% | -78.52% | -650.55% | -4,205.51% | -8,825.00% | -12,800.00% |
| Income Tax Expense | 289.50M | 223.30M | 118.10M | 124.10M | -60.50M | 169.70M | 351.60M | 346.50M | 392.80M | 185.11M | 104.34M | 136.23M | 81.87M | 41.92M | -695.00K | -29.51M | -3.28M | -34.06M | -17.49M | -3.03M | -2.51M | 5.44M | -9.65M | -5.89M | -1.90M | 0.00 |
| Net Income | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M | 589.20M | 417.90M | 713.70M | 651.64M | 340.07M | 174.56M | 304.44M | 217.87M | 105.92M | 19.46M | -42.79M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.50M | -12.80M |
| Net Income Ratio | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | 36.20% | 24.22% | 44.64% | 44.46% | 26.39% | 15.63% | 33.23% | 29.32% | 17.54% | 5.26% | -15.20% | 9.41% | 46.33% | 56.09% | 20.99% | -18.69% | -78.52% | -650.55% | -3,689.55% | -8,375.00% | -12,800.00% |
| EPS | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 | 14.17 | 7.06 | 3.49 | 5.84 | 3.81 | 1.89 | 0.37 | -0.93 | 0.47 | 1.61 | 1.43 | 0.36 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| EPS Diluted | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | 13.39 | 9.31 | 15.25 | 12.72 | 6.28 | 3.28 | 5.71 | 3.67 | 1.78 | 0.35 | -0.93 | 0.44 | 1.53 | 1.29 | 0.33 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| Weighted Avg Shares Out | 46.80M | 45.50M | 44.90M | 44.20M | 43.80M | 43.50M | 44.00M | 43.80M | 46.00M | 48.18M | 50.08M | 52.09M | 57.16M | 56.14M | 53.31M | 45.80M | 42.45M | 46.02M | 45.65M | 43.45M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
| Weighted Avg Shares Out (Dil) | 49.70M | 48.50M | 47.30M | 44.60M | 43.80M | 44.00M | 44.90M | 46.80M | 51.22M | 54.16M | 53.23M | 53.28M | 59.40M | 59.52M | 56.13M | 45.80M | 44.90M | 48.28M | 50.41M | 46.70M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
The 3 Best Medical Device Stocks to Buy in June 2024
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
Why Is United Therapeutics (UTHR) Up 4.8% Since Last Earnings Report?
Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Source: https://incomestatements.info
Category: Stock Reports